Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies are discussed. In the area of experimental design, issues that must be considered include randomization of animals, sample size considerations, dose selection and allocation of animals to experimental groups, and control of potentially confounding factors.
Introduction
Although the overall evaluation of the results of a carcinogenicity study in laboratory animals is a complex process involving scientific judgment with all its frailties, the process is made less difficult if the experiment has been properly designed, the data appropriately analyzed and certain interpretative issues adequately addressed.
The purpose of this paper is to consider in detail each of these important areas. Statistical design issues include proper randomization of animals, sample size considerations, dose selection and animal allocation issues, and the control of potentially confounding factors such as littermate and caging effects. Data analyses should employ methodology that takes survival differences into account and ideally makes use of cause of death information. Issues of interpretation include the use of historical controls, awareness of the falsepositive issue and the consideration of negative trends. 
Experimental Design
If a study has been inadequately designed, no amount ofcareful histopathological evaluation or elegant statistical analysis can salvage the experiment. Many design issues are "nonstatistical" and will not be dealt with here. They include species and strain ofanimal employed in the experiment, route of administration, diet, study duration, caging, intercurrent infectious diseases and chemical stability. If one or more of these factors is compromised, the interpretability of the study becomes more difficult. The "statistical" design issues are discussed below.
Randomization
Animals should be randomly assigned to treated or control groups to insure that there is no selection bias in the formulation of these groups. In some instances, a stratified random sampling scheme may be appropriate: for example, where animals are first stratified by body weight and then assigned at random to treated or control groups. In any case, some formal randomization scheme should be employed rather than relying on subjective judgment for assigning animals to treated and control groups.
Sample Size Considerations
A sufficient number of animals should be included in the experimental design to insure reasonable power for detecting carcinogenic effects. The "standard" NCI design employs 50 animals in each of three groups: control, low dose and high dose. Table 1 shows the approximate power of this particular design for detecting carcinogenic effects. The actual number of animals per group will depend upon the specific study objectives, but one should always consider the power of the design before the experiment is begun. If interim kills are to be employed, allowance for these extra animals must be made in the overall experimental design.
Dose Selection and Allocation of Animals
Perhaps no single issue related to the design of laboratory animal carcinogenicity studies has generated as much discussion as has dose selection. Since small numbers of rodents are serving as surrogates for a large human population, and since even the most carefully documented human carcinogens (e.g., cigarette smoking) do not produce tumors in the majority of subjects at risk, there is general acceptance of the basic principle that animal testing must be carried out at doses that exceed a typical human exposure (1) (2) (3) (4) (5) . Large doses must be employed to insure reasonable power for detecting carcinogenic effects. However, there continues to be debate regarding the actual magnitude of doses that should be employed in these investigations.
Dose selection for the chronic study is generally based on the results of a series of subehronic (singledose, two-week, and 90-day) toxicity studies. Data from these experiments that are factored into the dose selection process include weight gain and survival information, pharmacokinetic and metabolism data, and the results of a thorough histopathological examination.
Sontag et al. (6) recommend that the highest dose employed should be the "maximum tolerated dose" (12, 13) investigated various allocations of animals to derive an "optimal design," where optimality was defined in terms of the power of the design, the variability of low-dose risk estimates and the accuracy of estimating the dose-response curve in the experimental region. Their final recommended design is given in Table 2 and involves unequal allocation of animals to dosed and control groups.
Confounding Factors
If certain factors can be identified that would otherwise confound the interpretation of the study, then the experimental design should be modified to take these factors into account. One example is cage location, which in several studies (14, 15) has been shown to be related to increased incidences of cataracts and retinopathy (because of the proximity of the animals to the fluorescent light source). This particular problem can be dealt with by a systematic rotation of cages. In addition to cage location, the housing of more than one animal per cage may introduce "cage effects" that require consideration in the subsequent statistical analysis (16) .
Littermates may also be a potentially confounding factor. Littermate information is generally not available when the animals are received from the supplier and it is implicitly assumed (reasonably in most cases) that any "litter effects" have been "balanced out" by the random assignment of animals to treated or control groups. Specialized methods of analysis have been proposed (17, 18) if it is desired to employ a formal litter-matched design.
A more subtle potential source of bias is a difference in slide preparation of tissues for histopathological examination. Ideally, identical procedures should be employed for dosed and control groups with regard to the number of slides prepared and the methodology employed. Occasionally, additional slides may be made for a particular animal because of suspicious "lumps and bumps" noted at gross necropsy, but the investigator must be careful that these additional slides do not introduce bias into the diagnostic process. For example, if for a particular organ consistently more sections are examined for dosed animals than for controls, one would expect to find more dosed-group tumors by chance alone.
A related issue is "blind" pathology, which has traditionally been the source of debate between statisticians and pathologists. Most statisticians recommend "blind" pathology (i.e., histologic examination without knowing the source of the tissue) to insure the total objectivity of the tumor diagnosis. Otherwise, subjective bias could effect the overall interpretation of the results.
On the other hand, most pathologists feel that the disadvantages of "blind" pathology outweigh the advantages (19) . They assert that control animals must be examined first to determine the naturally occurring incidence and severity of neoplastic and nonneoplastic lesions. They further contend that blind pathology will require additional time and effort and will introduce the possibility of coding errors, and that an experienced pathologist can generally distinguish between tissues from control and treated animals in any event.
Perhaps a reasonable compromise (currently employed by the NTP) is to have the original pathologist diagnose lesions in a nonblind fashion. Then, if apparent treatmentrelated effects are found, these particular tissues can then be reviewed blindly to determine whether or not these lesions can be verified under a more rigorous protocol. If this procedure reveals evidence of bias on the part of the original pathologist, this raises serious questions regarding the objectivity of all his pathology diagnoses, including those which showed no apparent treatment-related effects.
Methods of Statistical Analysis
If a study has been properly designed and executed, the statistical analysis of the data is obviously facilitated. The methods of analyses traditionally used by the NCI in the evaluation of tumor incidence data were Fisher's exact test for pairwise comparisons and the CochranArmitage test for dose-response trends (20) . These procedures compare directly the proportion of tumorbearing animals in dosed and control groups.
In recent years there has been an increased awareness of the need to take intercurrent mortality into account in the analysis of tumor incidence data. Consequently, a number of different methods have been proposed that deal with time-to-death-with-tumor (21-28).
One simple approach to this problem (used, e.g., in many of the early NCI studies) is to exclude all animals that died prior to the appearance of the first tumor, and then carry out the analyses described above (Fisher's exact test; Cochran-Armitage test). In some cases this approach will be satisfactory, but in other instances more rigorous methods of analysis may be required.
Perhaps the most comprehensive discussion of this issue is given by Peto et al. (25) . These authors emphasize the need to determine the "context of observation" of each tumor, i.e., to determine whether the tumor contributed directly or indirectly to the cause of death or whether alternatively the tumor was merely an incidental finding at autopsy in an animal dying of an unrelated cause. The distinction between "fatal" and "incidental" tumors is important, because in the evaluation of tumor incidence it is essential to distinguish between a chemical that reduces survival because of shortened tumor latency (a real carcinogenic effect) and one which also reduces survival, but in which tumors are merely being observed earlier because animals are dying of some other competing risk (a noncarcinogenic effect). Hoel and Walburg (21) These methods can also be used to pool the "fatal tumor" analysis with the corresponding comparisons based on the "incidental tumors" observed at the end of the experiment to obtain an overall p value. Life table methods are sensitive both to an increased tumor incidence and to a shortened latency period.
For nonfatal tumors, the procedure described by Peto et al. (25) , which is ssentially the Hoel-Walburg (21) method, can be employed. According to this approach, the proportions of animals found to have tumors in dosed and control groups are compared at selected time intervals. The denominators of these proportions are the number of animals actually autopsied during the time interval. The individual time interval comparisons are then combined by Mantel-Haenszel methods to obtain a single overall result. An example illustrating the numerical computations for these various methods of analysis is given in the Appendix.
One disadvantage of the incidental tumor test is that a subjective determination of time intervals is required for purposes of grouping the data. A further drawback is that for studies in which reduced survival in the dosed group is severe, the method will have little power because only those tumors for which there is overlapping survival in dosed and control groups will be included in the statistical analysis. An alternative method of analysis for incidental tumors currently being studied by the NTP is based on logistic regression (28) . In addition to avoiding the disadvantages cited above, the logistic regression approach allows the investigator to take into account certain covariables (e.g., cage location, litter effects) that might otherwise be confounding factors in the overall evaluation of the data.
Most statisticians (20, 25) seem to believe that onetailed tests are generally preferable to two-tailed tests in the evaluation of tumor incidence data. The reason for this preference is that the primary objective of these studies is to identify carcinogens (a one-tailed alternative).
In any case, it should be clearly stated which is being used when p values are reported.
Despite the fact that past interpretations of carcinogenicity data have tended to focus on pairwise comparisons in general and high-dose effects in particular (32) , the importance of trend tests should not be overlooked. Indeed, Peto et al. (25) state that trend tests combine 'in a reasonably optimal way (and should therefore usually supercede)" the infornation obtained from pairwise comparisons. Since trend tests utilize information from all experimental groups simultaneously, they are more sensitive than pairwise comparisons to the detection of carcinogenic effects, which is an advantage that becomes more important as the number of dosed groups increases. Ironically, this very sensitivity seems to have limited the subjective value placed on these tests in the past by some investigators, namely because of the fear of making "false positive" decisions (see discussion of this issue below). Increasing emphasis will likely be given to trend tests (1) as standard designs begin utilizing additional dosed groups, (2) as more knowledge is gained regarding the likelihood of false positive results, and (3) as more information is learned about the patterns of chemically induced dose-response trends.
Interpretation of the Data
Even if a study has been carefully designed and appropriate statistical methodology employed, interpretation of results is a complex process. The following factors merit special consideration: use of historical control data, multiple comparisons issues, and interpretation of increased and decreased tumor incidence.
Historical Control Data
Over the past several years, NCI and NTP have accumulated considerable information on background tumor rates in mice and rats, particularly the B6C3F1 mouse and the Fischer 344 rat. The concurrent control group is always the most important control group used in the decision making process. However, there are some instances in which the use of historical control data can aid an investigator in the evaluation of tumor incidence data. Two examples are rare tumors and tumors that show a marginal increase relative to concurrent controls (33) .
Before historical control data can be used in a meaningful way, however, there are a number of problems that must first be addressed. For example, nomenclature differences must be resolved. That is, nomenclature conventions and diagnostic criteria should be identical for all studies in the historical control database. Then, a decision has to be made regarding which studies should be included in the database. Next, the sources of variability in historical control tumor rates must be identified, and if possible, controlled. There are certain tumors that show considerable (extrabinomial) study-to-study variability. What should be kept in mind that the false positive "problem" is limited primarily to common tumors, since for rare tumors it is virtually impossible for a sufficient number to occur in any one study by chance alone to lead to a statistically significant result.
One possible strategy to deal with this problem (employed, e.g., in the early NCI bioassays) is to use a Bonferonni-type multiple comparisons adjustment. A discussion of Bonferonni adjustments has been given by Mantel (16) .
Because interpretation of carcinogenicity data is a complex process, other investigators believe that it is not necessary to employ any formal rigid multiplecomparisons adjustment. As noted by Peto et al. (25) , "P-values are objective facts, but unless a p-value is very extreme, the proper use of it in the light of other information to decide whether or not the test agent really is carcinogenic involves subjective judgement!' Thus, no rigid "decision rule" should be employed in the interpretation of carcinogenicity data. Although the statistical significance of an observed tumor increase is perhaps the single most important piece of evidence used in the evaluation process, a number of other factors must be taken into account as well: (1) whether the effect was dose-related, (2) whether the effect was supported by related nonneoplastic changes and/or by similar evidence in other sex-species groups, (3) whether the effect occurred in a target organ, (4) relative survival of dosed and control animals, (5) the historical rate of the particular tumor, and (6) the biological "meaningfulness" of the effect.
Are false positives a major problem in NCI/NTP carcinogenicity studies? Certain investigations of this issue (which assumed that any p < 0.05 effect was automatically regarded as biologically meaningful) estimated these rates to be quite high: 20 to 50% for a single sex-species group (38) . Other investigators questioned the validity of this particular decision rule and emphasized (as discussed above) that the interpretation of carcinogenicity results incorporates biological knowledge and corroborative evidence such as the presence of a dose-response relationship or experimentally consistent results in different species or sexes (39) . These investigators and other researchers (20, 40) concluded that the overall false-positive rate generally does not greatly exceed the nominal level.
In a recent examination of 25 NTP feeding studies, a simple statistical rule was derived which appears to mimic closely the scientific judgment process used in these experiments. This "rule" was as follows: regard as carcinogenic any chemical that produces a high-dose increase in a common tumor that is statistically significant at the 0.01 level or a high-dose increase in an uncommon tumor that is statistically significant at the 0.05 level. It should be re-emphasized that no rigid decision procedure was (or should be) used in these studies. However, the overall false-positive rate associated with this particular decision rule (which appears to closely approximate the overall evaluation process) was estimated and found to be no more than 7 to 8% (41) . Thus, false positives do not appear to be a major problem in NCI/NTP studies.
Increased and Decreased Tumor Incidences
One noteworthy characteristic of NCI/NTP carcinogenicity studies is the tendency of these experiments to show significantly decreased as well as increased tumor incidences. In fact, an examination of 25 recent NTP feeding studies revealed that the frequencies of statistically significant (p < 0.01) increases and decreases in tumor incidence in these studies were approximately the same (42) . Some investigators have responded to these types of findings by taking the position that such studies are uninterpretable, should be abandoned altogether, and a "drastically different design" employed (43) .
Other authors feel that a more prudent and scientific course of action is to investigate the patterns of tumor increases and decreases and attempt to identify possible causal factors, as well as to better characterize the biologic process or processes responsible for these opposing responses (44) . Survival differences can account for many of the decreased tumor incidences observed in dosed groups, since if the chemical's toxic effect results in early mortality, these animals may not have survived sufficiently long to be considered at risk for developing tumors.
Another explanatory factor is decreased weight gain. Frequently, the chemical under test reduces body weight gain, and decreased incidences of certain endocrine and reproductive system tumors (notably mammary gland fibroadenoma in female F344 rats) are clearly related to decreased weight gain in the dosed groups (42) . This result agrees with similar observations made in earlier studies (45) (46) (47) (48) (49) .
Haseman (42) also found an inverse correlation between the incidences of liver tumors and leukemia in F344 rats. A similar negative association between the incidences of lymphomas and liver tumors in CF-1 mice exposed to DDT was reported by Breslow et al. (50) . This result was confirmed in a later study (51) that involved extensive serial sacrifice and thus overcame doubts about whether the original finding may have been an artifact of the rapid lethality of lymphomas. The point is that while one should not ignore negative trends in tumor incidence, a closer examination of the data may in many cases reveal possible associations that may serve as explanatory factors. Also, one should not rule out the possibility that in some instances certain chemicals may in fact exhibit "true" anti-carcinogenic effects.
Appendix
In this section we give a detailed comparison of the three methods of analysis used most often in the analysis of tumor incidence data: the fatal tumors (life-table) analysis, Peto's incidental tumors analysis and the Cochran-Armitage linear trend test.
The discussion that follows deals with only the trend tests but similar comments apply for the pairwise comparisons. All three test procedures follow the same basic approach: (1) break down the data by time interval; (2) calculate expected number of tumors in each time interval; (3) calculate the corresponding variance term V; (4) combine the data over all time intervals, compare observed and expected tumor incidence, and calculate the final test statistic.
The primary differences between the procedures are as follows.
The Cochran-Armitage test in essence uses a single time interval (the entire study period) and hence does not adjust for intercurrent mortality. In situations in which there is a marked treatment effect on survival, this can be a serious shortcoming of this approach.
The fatal tumors analysis assumes that all tumors of a given type in animals dying prior to terminal sacrifice (TS) are "fatal," (i.e., either directly or indirectly caused the death of the animal). The incidental tumors analysis assumes that all such tumors are 'incidental," (i.e., were merely observed at autopsy in animals dying of an unknown or unrelated cause). At present NTP protocols do not require specification of the cause of death for each individual animal, so it is not possible to determine precisely which tumors are fatal and which are incidental. The Cochran-Armitage test does not require an assumption regarding tumor "lethality" For a particular time interval the fatal tumors analysis is based on all animals alive at the beginning of the interval. In contrast, the incidental tumors analysis is based only on the animals that die and are autopsied during the interval.
For the fatal tumors analysis, each week at which a tumor is observed is regarded as a separate "time The p-value that corresponds to this test statistic can be found from tables of the Standard Normal Table A For these data, adjusting for intercurrent mortality revealed some evidence of a dose-related trend that would have been missed had the usual Cochran-Armitage test been carried out. This latter test does not take into account the fact that at the high dose 44% of the animals died during the first year (compared with 4% of the controls) and the first malignant lymphoma was not observed until week 73.
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